This is a review about VEGF, based on 74 published articles (read how Labome selects the articles), using VEGF antibody in all methods. It is aimed to help Labome visitors find the most suited VEGF antibody.
VEGF synonym: MVCD1; VEGF; VPF; vascular permeability factor

Santa Cruz BiotechnologySanta Cruz Biotechnology VEGF product
  • block or activateIn 2003, Tim D Eubank et al. used Santa Cruz Biotechnology VEGF antibody to study the effect of M-CSF on VEGF production in human monocytes [ncbi , more ].
  • flow cytometryIn 2002, Wataru Matsuyama et al. employed Santa Cruz Biotechnology VEGF antibody to study the effect of purified protein derivative of tuberculin on the expression of vascular endothelial growth factor in T lymphocytes in vitro [ncbi , more ].
  • immunohistochemistryIn 2010, Yi Ping Shih et al. employed Santa Cruz Biotechnology VEGF antibody to explore the effect of DLC1 on angiogenesis (catalog: sc-152) [ncbi , more ]. Santa Cruz Biotechnology VEGF antibody was employed in 2008 to investigate how the activation of TGFalpha-EGFR signaling in primary colon tumors contributes to the spread of tumor cells to the lymph nodes and liver [ncbi , more ], to study whether the expression of tyrosine kinase growth factor receptors is constant or varies between and within individual colon cancer neoplasms [ncbi , more ], to determine whether the heterogeneous clinical response to tumour necrosis factor (TNF) alpha blocking therapy in rheumatoid arthritis (RA) can be predicted by TNFalpha expression in the synovium before initiation of treatment [ncbi , more ], to perform immunohistochemistry in order to study the functions and relations of vascular endothelial growth factor (VEGF), advanced glycation end products (AGEs), VEGF receptor (flt-1), and macrophages in the progress of proliferative diabetic retinopathy [ncbi , more ]and to study the role for cyclin A1 in prostate cancer invasion and metastasis and the molecular mechanisms by which cyclin A1 contributes to tumor metastasis [ncbi , more ]. Santa Cruz Biotechnology VEGF antibody was utilized in 2007 to study angiopoietin-2 expression in human colorectal adenocarcinoma [ncbi , more ], to study the role of placenta growth factor in malignancy [ncbi , more ]and to investigate the effect of TA on early inflammation and vascular leakage in the retina of STZ-induced hyperglycemic rats [ncbi , more ]. In 2006, K Ino et al. used Santa Cruz Biotechnology VEGF antibody to study the effect of Angiotensin II type 1 receptor on ovarian cancer angiogenesis and patient survival [ncbi , more ]. John Ash et al. applied Santa Cruz Biotechnology VEGF antibody to determine how LIF could regulate ocular vascular development [ncbi , more ] in 2005 and Tomoyuki Okuda et al. used Santa Cruz Biotechnology VEGF antibody to hypoxia-inducible factor 1 alpha and vascular endothelial growth factor overexpression in ischemic colitis (catalog: sc-152) [ncbi , more ]. Santa Cruz Biotechnology VEGF antibody was employed in 2004 to study the value of the RECK and MMP-9 as prognostic indicator for colorectal cancer [ncbi , more ], to detect VEGF in morphologically normal human embryos [ncbi , more ]and to detect VEGF expression in human non small-cell lung cancer (NSCLC) [ncbi , more ]. J Sato et al. employed Santa Cruz Biotechnology VEGF antibody to study its expression in synovial tissues [ncbi , more ] in 2003 and Fabio Cianchi et al. used Santa Cruz Biotechnology VEGF antibody to study the expression of iNOS and its activity in human colorectal tumors [ncbi , more ]. In 2002, Kumi Yasukawa et al. used Santa Cruz Biotechnology VEGF antibody to provide evidence that there is systemic production of VEGF and flt-1 in acute Kawasaki disease [ncbi , more ].
  • immunoprecipitationIn 2003, Alessandro Marcello et al. used Santa Cruz Biotechnology VEGF antibody to study the interaction between cyclin T1 and PML protein within specific subnuclear compartments human HL3T1 and U2OS cells [ncbi , more ]. In 2001, I Huez et al. utilized Santa Cruz Biotechnology VEGF antibody to study a new vascular endothelial growth factor isoform (catalog: sc-152) [ncbi , more ].
  • western blotIn 2012, Hye Ji Cha et al. applied Santa Cruz Biotechnology VEGF antibody to perform Western blotting in order to study the effect of thiabendazole on human fibrosarcoma [ncbi , more ]. Santa Cruz Biotechnology VEGF antibody was utilized in 2010 to perform western blot in order to study a mechanism for [ncbi , more ], to carry out western blotting analysis in order to investigate the role of TNF-a in irradiation-induced bone marrow cell apoptosis and bone marrow dysfunction [ncbi , more ]and to carry out western blot analysis in order to investigate the precise contribution of 4E-BPs to mTORC1 signaling [ncbi , more ]. In 2009, Ivan Topisirovic et al. utilized Santa Cruz Biotechnology VEGF antibody to detect vascular endothelial growth factor in western blot in order to find out the novel mechanism by which eIF4E levels are regulated at the level of mRNA stability [ncbi , more ]. Santa Cruz Biotechnology VEGF antibody was employed in 2008 to study the role of MMP-2 inhibition in tumor cells by targeting angiogenic components of tumor growth [ncbi , more ], to demonstate that perfusion-type cyanine dyes allow assessment of angiogenesis in vivo using planar or tomographic imaging technology [ncbi , more ], to perform western blot in order to study the significant effect of prolidase in the hypoxia-inducible factor-1 (HIF-1) signaling and extracellular matrix [ncbi , more ]and to study the role of P58IPK in endoplasmic reticulum (ER) stress and apoptosis in human retinal capillary endothelial cells (HRCECs) [ncbi , more ]. Y H Kim et al. employed Santa Cruz Biotechnology VEGF antibody to investigate the effect of TA on early inflammation and vascular leakage in the retina of STZ-induced hyperglycemic rats [ncbi , more ] in 2007 and Alice P Taylor et al. used Santa Cruz Biotechnology VEGF antibody to study the role of placenta growth factor in malignancy [ncbi , more ]. Jinyi Shao et al. utilized Santa Cruz Biotechnology VEGF antibody to study the transcriptional stimulation in colon cancer by prostaglandin E2 [ncbi , more ] in 2005 and Kip M Connor et al. used Santa Cruz Biotechnology VEGF antibody to study the angiogenic phenotype regulation by mitochondrial H2O2 via PTEN oxidation [ncbi , more ]. In 2004, Allen D Everett et al. utilized Santa Cruz Biotechnology VEGF antibody to characterize hepatoma-derived growth factor [ncbi , more ]. Hiroki Kuniyasu et al. applied Santa Cruz Biotechnology VEGF antibody to study the production of interleukin 15 by human colon cancer cells associated with induction of mucosal hyperplasia, angiogenesis, and metastasis [ncbi , more ] in 2003 and Raffaella Giavazzi et al. used Santa Cruz Biotechnology VEGF antibody to study the relative impact of fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF) on tumor growth and neovascularization [ncbi , more ]. In 2002, Gakuji Hashimoto et al. used Santa Cruz Biotechnology VEGF antibody to study the activity of matrix metalloproteinases to cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165 [ncbi , more ]. In 2001, I Huez et al. utilized Santa Cruz Biotechnology VEGF antibody to study a new vascular endothelial growth factor isoform (catalog: sc-152) [ncbi , more ].
R and D SystemsR and D Systems VEGF product
  • block or activateIn 2005, Kip M Connor et al. employed R and D Systems VEGF antibody to the angiogenic phenotype regulation by mitochondrial H2O2 via PTEN oxidation [ncbi , more ]. In 2001, T Veikkola et al. utilized R and D Systems VEGF antibody to study the role for the VEGFR-3 signal transduction pathway in inducing specifically lymphangiogenesis in vivo [ncbi , more ].
  • ELISAIn 2012, Hye Ji Cha et al. utilized R and D Systems VEGF antibody to perform ELISA in order to study the effect of thiabendazole on human fibrosarcoma [ncbi , more ]. In 2009, Marc McClelland et al. applied R and D Systems VEGF antibody to demonstrate whether the expression of CD74 is associated with the angiogenic activity and level of CXC chemokine expression in human specimens of non-small cell lung cancer [ncbi , more ]. In 2006, Kenji Uchimura et al. applied R and D Systems VEGF antibody to study the HSulf-2 which selectively mobilizes heparin-bound growth factors and chemokines [ncbi , more ]. Raju R Raval et al. used R and D Systems VEGF antibody to study the differing effect of HIF1 and HIF2 in von Hippel-Lindau-Associated renal cell carcinoma [ncbi , more ] in 2005 and Jinyi Shao et al. used R and D Systems VEGF antibody to study the transcriptional stimulation in colon cancer by prostaglandin E2 [ncbi , more ]. Francesca Spinella et al. employed R and D Systems VEGF antibody to study the role for endothelin-1-induced prostaglandin E2-EP2, EP4 signaling in regulating vascular endothelial growth factor production and ovarian carcinoma cell invasion [ncbi , more ] in 2004 and Kornelija Kahlina et al. used R and D Systems VEGF antibody to study the expression of p68 DEAD box RNA helicase in keratinocytes [ncbi , more ]. R and D Systems VEGF antibody was employed in 2003 to study the expression of macrophage migration inhibitory factor and CXC chemokine in non-small cell lung cancer [ncbi , more ], to provide evidence that autocrine-paracrine VEGF loops may functionally operate in the maturation of megakaryocytic precursors through Flt1 receptor [ncbi , more ]and to study the migratory-adhesive switch in Ewing's Sarcoma Cells triggered by matrix metalloproteinase-9 silencing [ncbi , more ]. In 2002, Wataru Matsuyama et al. employed R and D Systems VEGF antibody to study the effect of purified protein derivative of tuberculin on the expression of vascular endothelial growth factor in T lymphocytes in vitro [ncbi , more ].
  • immunohistochemistryIn 2008, Sirirat Reungjui et al. used R and D Systems VEGF antibody to investigate whether hypokalemic nephropathy might also involve impaired renal angiogenesis [ncbi , more ]. In 2006, Adrian M Jubb et al. used R and D Systems VEGF antibody to evaluate VEGF thrombospondin-2 (THBS-2), and microvessel density (MVD) as prognostic factors and/or predictors of benefit from bevacizumab [ncbi , more ]. In 2005, Arno Kuijper et al. applied R and D Systems VEGF antibody to study its expression in breast fibroepithelial tumors [ncbi , more ]. In 2004, Ronnie T Poon et al. applied R and D Systems VEGF antibody to detect VEGF in HCC tumor section [ncbi , more ].
  • western blotIn 2009, Koji Taniguchi et al. applied R and D Systems VEGF antibody to investigate the role of sproutys in the regulation angiogenesis and ischemia in mice [ncbi , more ]. In 2005, Ye Zhou et al. applied R and D Systems VEGF antibody to study the relationship between FPR expression and the biologic behavior of glioma cells [ncbi , more ].
EMD MilliporeEMD Millipore VEGF product
  • block or activateIn 2002, Gakuji Hashimoto et al. used EMD Millipore VEGF antibody to study the activity of matrix metalloproteinases to cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165 [ncbi , more ].
  • immunohistochemistryIn 2008, G Bocci et al. employed EMD Millipore VEGF antibody to investigate the effect of metronomic irinotecan chemotherapy on colorectal cancer cells [ncbi , more ]. In 2006, Goutam Chakraborty et al. applied EMD Millipore VEGF antibody to study the role for the effect of hypoxia on cross-talk between Syk and Lck in breast cancer progression and angiogenesis [ncbi , more ]. In 2004, Pia Wülfing et al. employed EMD Millipore VEGF antibody to study the correlation of ET axis expression with VEGF and angiogenesis in breast cancer [ncbi , more ]. In 2003, Linda S Gutierrez et al. utilized EMD Millipore VEGF antibody to study the effects of TSP-1 on adenoma formation and development into cancerous lesions [ncbi , more ]. In 2002, Chang Wei Feng et al. used EMD Millipore VEGF antibody to study the correlation of expression of p53, VEGF, and iNOS and clinical features in gastric carcinogenesis [ncbi , more ]. In 2001, B Moller et al. utilized EMD Millipore VEGF antibody to detect VEGF in biopsies from both the anterior and posterior walls of the patients uterus [ncbi , more ].
  • western blotCharles N Landen et al. employed EMD Millipore VEGF antibody to study the effects of reduced EphA2 levels on tumor growth and the tumor microenvironment in an orthotopic ovarian cancer model [ncbi , more ] in 2006 and Goutam Chakraborty et al. used EMD Millipore VEGF antibody to study the role for the effect of hypoxia on cross-talk between Syk and Lck in breast cancer progression and angiogenesis [ncbi , more ]. In 2004, Mark G Slomiany et al. employed EMD Millipore VEGF antibody to study the role of HIF-1alpha in various neovascular diseases of the eye [ncbi , more ]. M K Tee et al. utilized EMD Millipore VEGF antibody to study a noval precursor form of vascular endothelial growth factor [ncbi , more ] in 2001 and B Moller et al. used EMD Millipore VEGF antibody to detect VEGF in biopsies from both the anterior and posterior walls of the patients uterus [ncbi , more ].
Thermo Scientific Pierce ProductsThermo Scientific Pierce Products VEGF product
  • immunohistochemistryIn 2008, Hua Chuan Zheng et al. used Thermo Scientific Pierce Products VEGF antibody to investigate the pathobiological behaviors of gastric mixed-type (MT) carcinomas and gastric carcinogenesis [ncbi , more ]. In 2007, T Misu et al. applied Thermo Scientific Pierce Products VEGF antibody to study the pathogenetic role of the AQP4 in NMO [ncbi , more ]. In 2004, Gassimou Bangoura et al. used Thermo Scientific Pierce Products VEGF antibody to study the expression of HIF-2a/EPAS1 in hepatocellular carcinoma [ncbi , more ].
Novus BiologicalsNovus Biologicals VEGF product
  • western blotIn 2010, Mi Ni Lee et al. employed Novus Biologicals VEGF antibody to investigate whether the arrest-defective protein 1 and hypoxia-inducible factor 1alpha had roles in tumor growth and metastasis [ncbi , more ]. In 2009, Sandra Rebouissou et al. used Novus Biologicals VEGF antibody to study the role for activated gp130 in inflammatory hepatocellular tumours [ncbi , more ].
EpitomicsEpitomics VEGF product
  • western blotIn 2009, Jin Bo Wang et al. used Epitomics VEGF antibody to investigate the role of curcumin in the regulation of the expression of PPARdelta, 14-3-3epsilon, and VEGF in HT-29 cells [ncbi , more ].
AbcamAbcam VEGF product
  • western blotIn 2009, Vinicio A de Jesus Perez et al. applied Abcam VEGF antibody to study the role for bone morphogenetic protein 2 in inducing pulmonary angiogenesis and its mechanism [ncbi , more ].
BD Biosciences
  • western blotIn 2008, Ramaswamy Bhuvaneswari et al. utilized BD Biosciences VEGF antibody to study the angiogenic responses at hypericin-PDT (HY-PDT) treatment in a human bladder carcinoma xenograft model [ncbi , more ].
Sigma-AldrichSigma-Aldrich VEGF product
  • western blotIn 2010, Daisuke Kamei et al. applied Sigma-Aldrich VEGF antibody to investigate the role of mPGES-1 in the regulation of tumour growth, invasion, and metastasis [ncbi , more ]. In 2004, Francesca Spinella et al. employed Sigma-Aldrich VEGF antibody to study the role for endothelin-1-induced prostaglandin E2-EP2, EP4 signaling in regulating vascular endothelial growth factor production and ovarian carcinoma cell invasion [ncbi , more ].
DakoDako VEGF product
  • immunohistochemistryIn 2008, J H Holstein et al. applied Dako VEGF antibody to analyze the effect of rapamycin treatment on bone repair [ncbi , more ].
MAXIN CO
  • immunohistochemistryIn 2002, Zheng Jun Song et al. employed VEGF antibody to study the relationship between the expression of inducible nitric oxide synthase (iNOS), vascular endothelial growth factor (VEGF), the microvascular density (MVD), and the pathological features and clinical staging of gastric cancer [ncbi , more ].
PeproTech
  • western blotIn 2009, Koji Taniguchi et al. applied PeproTech VEGF antibody to investigate the role of sproutys in the regulation angiogenesis and ischemia in mice [ncbi , more ].
cedarlanelabs
  • immunocytochemistryIn 2009, D Kika Veljkovic et al. employed cedarlanelabs VEGF antibody to carry out western blot analysis and immunofluorescence assays in order to investigate the association for increased expression of urokinase plasminogen activator and megakaryocyte differentiation in Quebec platelet disorder [ncbi , more ].
  • western blotIn 2009, D Kika Veljkovic et al. employed cedarlanelabs VEGF antibody to carry out western blot analysis and immunofluorescence assays in order to investigate the association for increased expression of urokinase plasminogen activator and megakaryocyte differentiation in Quebec platelet disorder [ncbi , more ].
Biogenex
  • immunohistochemistryIn 2004, Anna Maria Granato et al. applied Biogenex VEGF antibody to detect VEGF in tumor tissue from patients with breast cancer [ncbi , more ].
Articles Reviewed
  1. Hye Ji Cha et al. (2012). "Evolutionarily repurposed networks reveal the well-known antifungal drug thiabendazole to be a novel vascular disrupting agent".PMID 22927795
  2. Yi Ping Shih et al. (2010). "DLC1 negatively regulates angiogenesis in a paracrine fashion".PMID 20861185
  3. Ryan J O Dowling et al. (2010). "mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs".PMID 20508131
  4. Bin Zhang et al. (2010). "Blocking the Wnt pathway, a unifying mechanism for an angiogenic inhibitor in the serine proteinase inhibitor family".PMID 20351274
  5. Mi Ni Lee et al. (2010). "Roles of arrest-defective protein 1(225) and hypoxia-inducible factor 1alpha in tumor growth and metastasis".PMID 20194889
  6. Ana Sofia Cachaço et al. (2010). "TNF-alpha regulates the effects of irradiation in the mouse bone marrow microenvironment".PMID 20126546
  7. Daisuke Kamei et al. (2010). "Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis".PMID 19845504
  8. Koji Taniguchi et al. (2009). "Suppression of Sproutys has a therapeutic effect for a mouse model of ischemia by enhancing angiogenesis".PMID 19424491
  9. Jin Bo Wang et al. (2009). "Curcumin suppresses PPARdelta expression and related genes in HT-29 cells".PMID 19294764
  10. Vinicio A de Jesus Perez et al. (2009). "Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways".PMID 19139264
  11. Marc McClelland et al. (2009). "Expression of CD74, the receptor for macrophage migration inhibitory factor, in non-small cell lung cancer".PMID 19131591
  12. Ivan Topisirovic et al. (2009). "Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer".PMID 19114552
  13. D Kika Veljkovic et al. (2009). "Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation".PMID 19029443
  14. Sandra Rebouissou et al. (2009). "Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours".PMID 19020503
  15. Barbara Wegiel et al. (2008). "Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis".PMID 18612129
  16. Takamitsu Sasaki et al. (2008). "Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model".PMID 18583324
  17. Bin Li et al. (2008). "P58(IPK) inhibition of endoplasmic reticulum stress in human retinal capillary endothelial cells in vitro".PMID 18568130
  18. Chandramu Chetty et al. (2008). "Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer".PMID 18559520
  19. Ramaswamy Bhuvaneswari et al. (2008). "Molecular profiling of angiogenesis in hypericin mediated photodynamic therapy".PMID 18549507
  20. J H Holstein et al. (2008). "Rapamycin affects early fracture healing in mice".PMID 18454167
  21. G Bocci et al. (2008). "Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib".PMID 18443598
  22. Alexander Wall et al. (2008). "Differentiation of angiogenic burden in human cancer xenografts using a perfusion-type optical contrast agent (SIDAG)".PMID 18331624
  23. Hua Chuan Zheng et al. (2008). "Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas".PMID 18266006
  24. Toshio Kuwai et al. (2008). "Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors".PMID 18202197
  25. Sirirat Reungjui et al. (2008). "Hypokalemic nephropathy is associated with impaired angiogenesis".PMID 18178802
  26. C A Wijbrandts et al. (2008). "The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium".PMID 18055470
  27. Akihiro Kakehashi et al. (2008). "Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy".PMID 18053608
  28. Arkadiusz Surazynski et al. (2008). "Extracellular matrix and HIF-1 signaling: the role of prolidase".PMID 17999410
  29. Y H Kim et al. (2007). "Triamcinolone acetonide protects the rat retina from STZ-induced acute inflammation and early vascular leakage".PMID 17881007
  30. Hong Ling Wang et al. (2007). "Expression of angiopoietin-2 is correlated with vascularization and tumor size in human colorectal adenocarcinoma".PMID 17785951
  31. T Misu et al. (2007). "Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis".PMID 17405762
  32. Alice P Taylor et al. (2007). "Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts".PMID 17308051
  33. Charles N Landen et al. (2006). "Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer".PMID 17077358
  34. Goutam Chakraborty et al. (2006). "Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis".PMID 16474166
  35. K Ino et al. (2006). "Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival".PMID 16434990
  36. Kenji Uchimura et al. (2006). "HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1".PMID 16417632
  37. Adrian M Jubb et al. (2006). "Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer".PMID 16365183
  38. Arno Kuijper et al. (2005). "Expression of hypoxia-inducible factor 1 alpha and its downstream targets in fibroepithelial tumors of the breast".PMID 16168127
  39. Raju R Raval et al. (2005). "Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma".PMID 15964822
  40. Ye Zhou et al. (2005). "Formylpeptide receptor FPR and the rapid growth of malignant human gliomas".PMID 15928303
  41. Jinyi Shao et al. (2005). "Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer".PMID 15899904
  42. John Ash et al. (2005). "Transgenic expression of leukemia inhibitory factor (LIF) blocks normal vascular development but not pathological neovascularization in the eye".PMID 15889014
  43. Tomoyuki Okuda et al. (2005). "Hypoxia-inducible factor 1 alpha and vascular endothelial growth factor overexpression in ischemic colitis".PMID 15770733
  44. Kip M Connor et al. (2005). "Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation".PMID 15701646
  45. Shinya Ishikawa et al. (2004). "Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer".PMID 15475447
  46. Francesca Spinella et al. (2004). "Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion".PMID 15347673
  47. Taku Takeuchi et al. (2004). "The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer".PMID 15328199
  48. Kornelija Kahlina et al. (2004). "p68 DEAD box RNA helicase expression in keratinocytes. Regulation, nucleolar localization, and functional connection to proliferation and vascular endothelial growth factor gene expression".PMID 15304501
  49. Ronnie T Poon et al. (2004). "Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma".PMID 15217952
  50. Mark G Slomiany et al. (2004). "Autocrine effects of IGF-I-induced VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line ARPE-19".PMID 15140752
  51. Pia Wülfing et al. (2004). "Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer".PMID 15073116
  52. Gassimou Bangoura et al. (2004). "Expression of HIF-2alpha/EPAS1 in hepatocellular carcinoma".PMID 14966910
  53. Allen D Everett et al. (2004). "Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor".PMID 14751852
  54. Karïn Gogat et al. (2004). "VEGF and KDR gene expression during human embryonic and fetal eye development".PMID 14691147
  55. Anna Maria Granato et al. (2004). "Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?".PMID 14680499
  56. Hiroki Kuniyasu et al. (2003). "Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis".PMID 14581351
  57. Tim D Eubank et al. (2003). "M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes".PMID 12928417
  58. Josiane Sancéau et al. (2003). "Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells".PMID 12847101
  59. Raffaella Giavazzi et al. (2003). "Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis".PMID 12759248
  60. Alessandro Marcello et al. (2003). "Recruitment of human cyclin T1 to nuclear bodies through direct interaction with the PML protein".PMID 12727882
  61. J Sato et al. (2003). "Correlations of the expression of fibroblast growth factor-2, vascular endothelial growth factor, and their receptors with angiogenesis in synovial tissues from patients with internal derangement of the temporomandibular joint".PMID 12651930
  62. Fabio Cianchi et al. (2003). "Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis".PMID 12598314
  63. Linda S Gutierrez et al. (2003). "Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model".PMID 12584168
  64. Eric S White et al. (2003). "Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis".PMID 12576459
  65. Ida Casella et al. (2003). "Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor".PMID 12406876
  66. Zheng Jun Song et al. (2002). "Relationship between the expression of iNOS,VEGF,tumor angiogenesis and gastric cancer".PMID 12174362
  67. Gakuji Hashimoto et al. (2002). "Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165".PMID 12114504
  68. Chang Wei Feng et al. (2002). "Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features".PMID 11978184
  69. Wataru Matsuyama et al. (2002). "Purified protein derivative of tuberculin upregulates the expression of vascular endothelial growth factor in T lymphocytes in vitro".PMID 11972637
  70. Kumi Yasukawa et al. (2002). "Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease".PMID 11839635
  71. I Huez et al. (2001). "New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation".PMID 11731620
  72. M K Tee et al. (2001). "A precursor form of vascular endothelial growth factor arises by initiation from an upstream in-frame CUG codon".PMID 11563986
  73. T Veikkola et al. (2001). "Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice".PMID 11250889
  74. B Moller et al. (2001). "Expression of the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle".PMID 11134362